Neuralstem has obtained notice of allowance for a patent that covers various methods to use expanded spinal cord stem cells such as NSI-566 to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The company completed Phase ...
Neuralstem has granted license to use its spinal cord delivery platform and floating cannula to Q Therapeutics. The delivery platform and floating cannula are designed for delivering therapeutic agents to the spinal cord of patients with ...
Tags: Neuralstem, license, delivery platform, floating cannula, Q Therapeutics